Latest Insider Transactions at Moon Lake Immunotherapeutics (MLTX)
This section provides a real-time view of insider transactions for Moon Lake Immunotherapeutics (MLTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MoonLake Immunotherapeutics to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MoonLake Immunotherapeutics's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 02
2023
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
74,911
+0.9%
|
$4,269,927
$57.37 P/Share
|
|
Oct 01
2023
|
Matthias Bodenstedt Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,972
-17.62%
|
-
|
|
Oct 01
2023
|
Matthias Bodenstedt Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
62,972
+9.21%
|
-
|
|
Oct 01
2023
|
Simon Sturge Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
342,980
-100.0%
|
-
|
|
Oct 01
2023
|
Simon Sturge Director |
BUY
Conversion of derivative security
|
Direct |
342,980
+50.0%
|
-
|
|
Oct 01
2023
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
41,981
-17.62%
|
-
|
|
Oct 01
2023
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
41,981
+23.06%
|
-
|
|
Oct 01
2023
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,527,477
-100.0%
|
-
|
|
Oct 01
2023
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
2,527,477
+45.5%
|
-
|
|
Oct 01
2023
|
Da Silva Jorge Santos Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,167,554
-69.59%
|
-
|
|
Oct 01
2023
|
Da Silva Jorge Santos Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
3,167,554
+27.12%
|
-
|
|
Jun 30
2023
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
800,000
+13.97%
|
$40,000,000
$50.0 P/Share
|
|
Jun 26
2023
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
450,000
+0.42%
|
$23,400,000
$52.64 P/Share
|
|
Apr 05
2023
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
98,090
-29.16%
|
-
|
|
Apr 05
2023
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
98,090
+50.0%
|
-
|
|
Apr 05
2023
|
Kristian Reich Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
500,006
-16.52%
|
-
|
|
Apr 05
2023
|
Kristian Reich Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
500,006
+50.0%
|
-
|
|
Apr 05
2023
|
Matthias Bodenstedt Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
557,931
-64.58%
|
-
|
|
Apr 05
2023
|
Matthias Bodenstedt Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
557,931
+35.43%
|
-
|
|
Mar 21
2023
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
238,511
+6.09%
|
$5,008,731
$21.7 P/Share
|
|
Mar 20
2023
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
588,589
+5.34%
|
$11,771,780
$20.29 P/Share
|
|
Apr 05
2022
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
2,850,000
+50.0%
|
$28,500,000
$10.0 P/Share
|
|
Apr 05
2022
|
Bihua Chen |
BUY
Conversion of derivative security
|
Indirect |
2,785,000
+46.42%
|
-
|
|
Apr 05
2022
|
Helix Holdings LLC |
BUY
Conversion of derivative security
|
Direct |
2,785,000
+46.42%
|
-
|
|
Oct 22
2020
|
Helix Holdings LLC |
BUY
Open market or private purchase
|
Direct |
430,000
+50.0%
|
$4,300,000
$10.0 P/Share
|
|
Oct 22
2020
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
430,000
+50.0%
|
$4,300,000
$10.0 P/Share
|